

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Androgen receptor; bromodomain containing 4 (BRD4)	<p>Mouse and cell culture studies suggest BRD4 inhibitors could be more effective than androgen receptor antagonists at treating castration-resistant prostate cancer (CRPC). In a human CRPC cell line, the BRD4 inhibitor JQ1 caused more potent suppression of androgen receptor-mediated gene transcription than the androgen receptor antagonist Xtandi enzalutamide. In a mouse xenograft model of human CRPC, JQ1 caused more potent tumor growth inhibition than Xtandi or vehicle. Next steps include developing a strategy to identify patients that would respond to BET bromodomain inhibitors in prostate and other cancers.</p> <p>Medivation Inc. and Astellas Pharma Inc. market Xtandi to treat prostate cancer.</p> <p>The corresponding author is a cofounder of OncoFusion Therapeutics Inc., which is collaborating with Medivation to evaluate OncoFusion's preclinical BET bromodomain inhibitors in undisclosed cancers and other indications.</p> <p>At least four other companies have BET bromodomain inhibitors in Phase I testing to treat various cancers.</p> <p>JQ1 is a research reagent.</p> <p>SciBX 7(18); doi:10.1038/scibx.2014.525 Published online May 8, 2014</p>	Composition-of-matter patents filed; licensed to Medivation	<p>Asangani, I.A. <i>et al. Nature</i>; published online April 23, 2014; doi:10.1038/nature13229</p> <p>Contact: Arul M. Chinnaiyan, University of Michigan Medical School, Ann Arbor, Mich. e-mail: arul@umich.edu</p>